A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Cluster headache
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 1 May 2019 to 1 Jul 2019.
    • 25 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.
    • 16 Nov 2016 Planned End Date changed from 1 Sep 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top